SMAD4 and neoplasm: Examination of the malignant pleural effusion showed the previous mutational profile, i.e., EGFR ex19del, MET amplification (76% of tumor cells with >6 copies, average MET-GCN/cell of 10.3, >10% with MET gene clusters), JAK3 amplification, and TP53, FGFR2, and SMAD4 mutation.